DILIGENCE & BUSINESS STRATEGY
Whether you are a company seeking funding or an investor considering an investment in the Cell and Gene Therapy space, DHC has the expertise to support your needs. Our most common offerings in the area of Diligence & Business Strategy (formerly known as Financing and Diligence) include:
Due Diligence:
We are frequently called upon by investors to perform due diligence on companies in the Cell and Gene Therapy space. Alternatively, for companies seeking investment, our mock diligence service can help ensure you are prepared for questions investors may raise.
Teach-ins:
Are you an experienced investor who is new to the complex world of cell and gene? Or an existing pharma or biotech company that has recently acquired a cell and gene asset? We provide customized Cell and Gene Therapy 101 teach-ins.
Message Optimization and Market Positioning:
Our unique combination of deep technical expertise and investor relations experience allows us to provide a candid assessment of your program and strategic planning for an optimal ‘pitch.’
Landscape Scanning:
Our knowledge of the Cell and Gene Therapy landscape can help you identify investment targets that are well-aligned with your portfolio objectives.
Whether you are a company seeking funding or an investor considering an investment in the Cell and Gene Therapy space, DHC has the expertise to support your needs. Our most common offerings in the area of Financing and Diligence include:
Due Diligence:
We are frequently called upon by investors to perform due diligence on companies in the Cell and Gene Therapy space. Alternatively, for companies seeking investment, our mock diligence service can help ensure you are prepared for questions investors may raise.
Message Optimization:
Our unique combination of deep technical expertise and investor relations experience allows us to provide a candid assessment of your program and strategic planning for an optimal ‘pitch.’
Bespoke Introductions:
We maintain continuous awareness of investors with interest in the Cell and Gene Therapy space, allowing us to provide introductions to motivated investors for high quality companies seeking funding.